Krystal Biotech, Inc. (KRYS)

Every figure this model derived for KRYS, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 14,556,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 845,631,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 1,059,648,000 AssetsCurrent 2026-06-30
current liabilities 127,397,000 LiabilitiesCurrent 2026-06-30
equity 1,359,126,000 StockholdersEquity 2026-06-30
ocf 272,338,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 440,484,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 54,682,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up KRYS on one particular measure came for.

RatioValue
cash operating margin58.64
current ratio8.32
current ratio reported8.32
dilution pct0.71
ebit yoy41.76
fcf margin58.52
operating margin44.89
owner earnings margin46.11
revenue growth22.63
revenue growth per share21.76
roic30.42
rule of 4067.52
sbc pct revenue12.41

What to be careful about

What this model itself distrusts about KRYS's figures. Written by the derivation as it ran, not added afterwards.